CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong
收藏  |  浏览/下载：21/0  |  提交时间：2022/12/23
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang
收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18
Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance 期刊论文
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 卷号: 202
作者:  Li, Na;  Mao, Weimin;  Gao, Yun;  Wang, Ding;  Song, Zhengbo
收藏  |  浏览/下载：49/0  |  提交时间：2021/08/31
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun
收藏  |  浏览/下载：38/0  |  提交时间：2021/11/01
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation 期刊论文
ONCOGENE, 2020, 卷号: 39
作者:  Jin, Ying;  Bao, Hua;  Le, Xiuning;  Fan, Xiaojun;  Tang, Ming
收藏  |  浏览/下载：26/0  |  提交时间：2020/11/26
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文
CANCER SCIENCE, 2019, 页码: 11
作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun
收藏  |  浏览/下载：21/0  |  提交时间：2020/07/01
Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines 期刊论文
ONCOLOGY LETTERS, 2019, 卷号: 18, 期号: 3, 页码: 2977-2984
作者:  Wang, Hui-Li;  Liu, Yan-Chun;  Long, Ming-Peng;  Zheng, Chuan;  Yang, Jia-Hui
收藏  |  浏览/下载：95/0  |  提交时间：2019/11/07
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology 期刊论文
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 卷号: 18, 页码: 17
作者:  Bing, Zhitong;  Cheng, Zhiyuan;  Shi, Danfeng;  Liu, Xinkui;  Tian, Jinhui
收藏  |  浏览/下载：91/0  |  提交时间：2019/10/09
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology 期刊论文
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 卷号: 18
作者:  Bing, Zhitong;  Cheng, Zhiyuan;  Shi, Danfeng;  Liu, Xinkui;  Tian, Jinhui
收藏  |  浏览/下载：74/0  |  提交时间：2019/03/27
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy 期刊论文
CLINICAL CANCER RESEARCH, 2018, 卷号: 24, 期号: 15, 页码: 3583-3592
作者:  Song, Jiangdian;  Shi, Jingyun;  Dong, Di;  Fang, Mengjie;  Zhong, Wenzhao
收藏  |  浏览/下载：63/0  |  提交时间：2018/10/10

©版权所有 ©2017 CSpace - Powered by CSpace